The Division of Molecular Hematology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0373, Japan.
J Hematol Oncol. 2011 Apr 1;4:13. doi: 10.1186/1756-8722-4-13.
FLT3 is a type III receptor tyrosine kinase. Mutations of FLT3 comprise one of the most frequently identified types of genetic alterations in acute myeloid leukemia. One-third of acute myeloid leukemia patients have mutations of this gene, and the majority of these mutations involve an internal tandem duplication in the juxtamembrane region of FLT3, leading to constitutive activation of downstream signaling pathways and aberrant cell growth. This review summarizes the current understanding of the effects of the downstream molecular signaling pathways after FLT3 activation, with a particular focus on the effects on transcription factors. Moreover, this review describes novel FLT3-targeted therapies, as well as efficient combination therapies for FLT3-mutated leukemia cells.
FLT3 是一种 III 型受体酪氨酸激酶。FLT3 的突变是急性髓细胞白血病中最常见的基因改变类型之一。三分之一的急性髓细胞白血病患者存在该基因的突变，这些突变大多涉及 FLT3 近膜区的内部串联重复，导致下游信号通路的组成性激活和异常细胞生长。这篇综述总结了目前对 FLT3 激活后下游分子信号通路影响的认识，特别关注对转录因子的影响。此外，本文还描述了新型的 FLT3 靶向治疗方法，以及针对 FLT3 突变白血病细胞的有效联合治疗方法。
